Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression

Oncogene

Volumn 35, Issue 5, 2016, Pages 549-557

  Shvab, A ^a   Haase, G ^a   Ben Shmuel, A ^a   Gavert, N ^a   Brabletz, T ^b   Dedhar, S ^c   Ben Ze'ev, A ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CALCIUM BINDING PROTEIN; EZRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN LINKED KINASE; NERVE CELL ADHESION MOLECULE L1; SECRETED MODULAR CALCIUM BINDING MATRICELLULAR PROTEIN 2; UNCLASSIFIED DRUG; WNT PROTEIN; SMOC2 PROTEIN, HUMAN;

ARTICLE; CALCIUM BINDING; CANCER GROWTH; CELL ADHESION; CELL CULTURE; CELL MOTILITY; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; COMPARATIVE STUDY; CONSENSUS SEQUENCE; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INTESTINAL STEM CELL; INTESTINE CRYPT; LIVER METASTASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; WNT SIGNALING PATHWAY; WOUND CLOSURE; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; CELL GROWTH; CELL MOTION; COLON TUMOR; DISEASE COURSE; GENETICS; INTESTINE; METABOLISM; METASTASIS; MOUSE; NUDE MOUSE; PATHOLOGY; STEM CELL; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CALCIUM-BINDING PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; DISEASE PROGRESSION; HETEROGRAFTS; HUMANS; INTESTINES; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; STEM CELLS; TRANSCRIPTIONAL ACTIVATION; WNT SIGNALING PATHWAY;

EID: 84957428255     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.127     Document Type: Article

References (32)

1. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
2. Polakis P. The many ways of Wnt in cancer. Curr Opin Genet Dev 2007; 17: 45-51.
3. Conacci-Sorrell M, Zhurinsky J, Ben-Ze'ev A. The cadherin-catenin adhesion system in adhesion, signaling and cancer. J Clin Invest 2002; 109: 987-991.
4. Brümmendorf T, Kenwrick S, Rathjen FG. Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations. Curr Opin Neurobiol 1998; 8: 87-97.
5. Hortsch M. Structural and functional evolution of the L1 family: are four adhesion molecules better than one? Mol Cell Neurosci 2000; 15: 1-10.
6. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058-2072.
7. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T et al. L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 2005; 168: 633-642.
8. Gavert N, Sheffer M, Raveh S, Spaderna S, Shtutman M, Brabletz T et al. Expression of L1-CAM and ADAM10 in human colon cancer cells induces metastasis. Cancer Res 2007; 67: 7703-7712.
9. Gavert N, Shvab A, Sheffer M, Ben-Shmuel A, Haase G, Bakos E et al. c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis. Cancer Res 2013; 73: 5754-5763.
10. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci 2010; 123: 2135-2143.
11. Ben-Shmuel A, Shvab A, Gavert N, Brabletz T, Ben-Ze'ev A. Global analysis of L1-transcriptomes identified IGFBP-2 as a target of ezrin and NF-κB signaling that promotes colon cancer progression. Oncogene 2013; 32: 3220-3230.
12. Munoz J, Stange D, Schepers A, van de Wetering M, Koo B, Itzkovitz S et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent '+4' cell markers. EMBO J 2012; 31: 3079-3091.
13. Vannahme C, Gosling S, Paulsson M, Maurer P, Hartmann U. Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochem J 2003; 373: 805-814.
14. Novinec M, Kovacic L, Skrlj N, Turk V, Lenarcic B. Recombinant human SMOCs produced by in vitro refolding: calcium binding properties and interactions with serum proteins. Protein Expr Purif 2008; 62: 75-82.
15. Liu P, Lu J, Cardoso W, Vaziri C. The SPARC-related factor SMOC-2 promotes growth factor-induced cyclin D1 expression and DNA synthesis via integrin-linked kinase. Mol Biol Cell 2008; 19: 248-261.
16. Thiery JP, Acloque H, Huang R, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
17. Serrano I, McDonald P, Lock F, Muller WJ, Dedhar S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat Commun 2013; 4: 2976.
18. Bornstein P, Sage H. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14: 608-616.
19. Liu P, Pazin D, Merson R, Albrecht K, Vaziri C. The developmentally-regulated Smoc2 gene is repressed by aryl-hydrocarbon receptor (Ahr) signaling. Gene 2009; 433: 72-80.
20. Rocnik E, Liu P, Sato K, Walsh K, Vaziri C. The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity. J Biol Chem 2006; 281: 22855-22864.
21. Maier S, Paulsson M, Hartmann U. The widely expressed extracellular matrix protein SMOC-2 promotes keratinocyte attachment and migration. Exp Cell Res 2008; 314: 2477-2487.
22. Milano S, Kwon W, Pereira R, Antonyak M, Cerione R. Characterization of a novel activated Ran GTPase mutant and its ability to induce cellular transformation. J Biol Chem 2012; 287: 24955-24966.
23. Merlos-Suarez A, Barriga F, Jung P, Iglesias M, Cespedes MV, Rossell D et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-524.
24. Uchida H, Yamazaki K, Fukuma M, Yamada T, Hayashida T et al. Overexpression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci 2010; 101: 1731-1737.
25. Schwitalla S, Fingerle A, Cammareri P, Nebelsiek T, Goktuna S et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013; 152: 25-38.
26. Pattabiraman D, Weinberg R. Tackling the cancer stem cells - what challenges do they pose? Nature Rev Drug Discov 2014; 13: 497-512.
27. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumor progression. Nat Rev Cancer 2005; 5: 744-749.
28. Brabletz T. EMT and MET in metastasis: where are the cancer stem cells? Can Cell 2012; 22: 699-701.
29. Gavert N, Vivanti A, Hazin J, Brabletz T, Ben-Ze'ev A. L1-mediated colon cancer metastasis does not require changes in EMT and cancer stem cell markers. Mol Can Res 2011; 9: 14-24.
30. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-2120.
31. Yan Z, Yin H, Wang R, Wu D, Sun W et al. Overexpression of integrin-linked kinase (ILK) promotes migration and invasion of colorectal cancer cells by inducing epithelial-mesenchymal transition via NF-κB signaling. Acta Histochem 2014; 116: 527-533.
32. Simons B, Clevers H. Stem cell self-renewal in intestinal crypt. Exp Cell Res 2011; 317: 2719-2724.